TY  - GEN
AU  - Borthakur,Gautam
AU  - Dombret,Herve
AU  - Schafhausen,Philippe
AU  - Brummendorf,Tim Henrik
AU  - Boissel,Nicolas
AU  - Jabbour,Elias
AU  - Mariani,Mariangela
AU  - Capolongo,Laura
AU  - Carpinelli,Patrizia
AU  - Davite,Cristina
AU  - Kantarjian,Hagop
AU  - Cortes,Jorge E
TI  - A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
SN  - 1592-8721
PY  - 2016///0209
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Benzamides
KW  - Blast Crisis
KW  - drug therapy
KW  - Drug Administration Schedule
KW  - Febrile Neutropenia
KW  - chemically induced
KW  - Female
KW  - Fusion Proteins, bcr-abl
KW  - genetics
KW  - Humans
KW  - Imatinib Mesylate
KW  - Leukemia, Myeloid, Accelerated Phase
KW  - Male
KW  - Middle Aged
KW  - Mucositis
KW  - Mutation
KW  - Philadelphia Chromosome
KW  - Protein Kinase Inhibitors
KW  - Pyrazoles
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.3324/haematol.2014.115279
ER  -